Navigation Links
ESBATech's Lead Antibody Fragment Enters Clinical Development for Ophthalmic Indications
Date:4/24/2008

ogy platform for therapeutic antibody fragments, we started preclinical development of ESBA105 in mid 2006. Now to move this swiftly into the clinic is a truly exciting time for the company. ESBA105 represents a new generation of antibody fragment therapeutics that have favourable biochemical properties over earlier classes of antibody fragments, such as high stability, solubility and high monomeric content. This allows us to deliver the drug topically, without any need to stabilize or modify the protein. Thanks to the small protein size as compared to conventional antibodies, ESBA105 efficiently penetrates into all segments of the eye, which results in a high local concentration where the drug is needed to inhibit inflammation. As this is associated with low systemic drug exposure, this novel therapeutic approach has a very low risk of provoking systemic adverse effects."

ESBATech is the first and only company to date that has successfully screened and characterized the entire human pool (1.5 million) of naturally occurring variable immunoglobulin (VH and VL) domains to select highly stable, soluble and monomeric single-chain antibody fragments frameworks. The company is advancing a pipeline of novel, antibody fragment therapeutics for topical and/or local delivery, to ensure safe and convenient patient therapy.

About ESBATech AG

ESBATech AG is a Zurich, Switzerland-based, privately held drug discovery and development company focused on advancing antibody fragments for therapeutic applications. The company applies its proprietary, fully human single-chain antibody frameworks to generate product candidates against targets of clinical relevance. ESBATech is focused on delivering high concentrations of its therapeutic antibody fragments to the targeted sites, in combination with extremely low systemic load, in order to achieve low risk of systemic drug reactions using topical and local delivery. Current venture investors include SV Life Sciences,
'/>"/>

SOURCE ESBATech AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
2. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
3. OncoMed Chooses SynCo Bio Partners to Fill and Finish its Lead Antibody
4. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
5. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
6. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
7. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
8. Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
9. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
10. Celltrion and CSL Announce Collaboration to Develop and Manufacture Monoclonal Antibody
11. Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Healthcare Services, Inc. ("DHS"), a portfolio company of GMH Ventures ... Equipment, Inc. ("Progressive") of Clarion, PA ... not disclosed. Progressive is a full service ... sleep, mobility, and respiratory products to customers in the western ...
(Date:1/14/2014)... PLYMOUTH, Minn. , Jan. 14, 2014   NuAire , a ... come to agreement with Hitachi Koki of ... centrifuges in North America . NuAire will utilize ... and Canada to offer assistance ...
(Date:1/14/2014)... 14, 2014 Equashield ( http://www.equashield.com ... drugs, today announced that it has achieved 60% ...   Equashield,s closed systems reduce the ... and other medical professionals who prepare and administer ...
Breaking Medicine Technology:Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2Equashield's Sales Grow by 60% in 2013 2
... Dec. 20 The largest study to examine,the ... depression,significantly worsens a patient,s adherence to highly active ... medication,can reverse this outcome, according to a study ... Group Health Cooperative published in the,current online issue ...
... NEW YORK, Dec. 20 Intra-Cellular Therapies, Inc. ... insomnia (SMI) Phase 2,clinical study using its drug ... receptor antagonist and represents an important new,approach to ... separation of 5-HT2A,and dopamine receptor modulatory activities, ITI ...
Cached Medicine Technology:Kaiser Permanente - Group Health Study Shows Depression Worsens HIV Treatment 2Kaiser Permanente - Group Health Study Shows Depression Worsens HIV Treatment 3Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia 2Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia 3Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia 4
(Date:4/17/2014)... Scientists have identified new pain relief targets that ... pain. BBSRC-funded researchers at King,s College London made ... nerves in the periphery of the body. , ... and identifying mechanisms underlying pain generation and our ... related side effects." , One potential side effect ...
(Date:4/17/2014)... today in PLOS Pathogens , children who live ... can mount an immune response to infection with malaria ... of high fever and illness and partially control the ... may help researchers develop future interventions that prevent or ... Each year, approximately 200 million cases of malaria occur ...
(Date:4/17/2014)... San Diego School of Medicine report that older women, ... major loss are more likely to be compassionate toward ... published in this month,s issue of the International ... are associated with better health and well-being as we ... improve the outcomes of individuals whose deficits in compassion ...
(Date:4/17/2014)... NY In a review published in the April ... president of The Feinstein Institute for Medical Research, says ... medical community,s approach to treating sepsis, which ... Americans. , Sepsis occurs when molecules released into the ... throughout the body. Inflammation is necessary for maintaining good ...
(Date:4/17/2014)... team has created a new technology for modifying ... travel the body and selectively target cancer and ... devices that monitor and modify human physiology is ... no existing technology enabled bioengineers to build such ... respond in a customized fashion. , "The project ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:Study sheds light on how the immune system protects children from malaria 2Health News:The ilk of human kindness 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Building 'smart' cell-based therapies 2
... Lab in Summit County ... Outside of ... a,cardiology testing and treatment facility located in Hudson, was recently,granted accreditation ... Accreditation of Echocardiography,Laboratories (ICAEL)., "We,re thrilled to have this accreditation, ...
... El-Deiry, MD, PhD, Professor of Medicine, Genetics, and Pharmacology ... been pursuing a cancer-targeting molecule called TRAIL and its ... and curtails tumor spread by binding to a specialized ... cancer patients who often have suppressed immunity, and for ...
... Plus PEG-INTRON Improve Efficacy and Lower Relapse Rates, ... the Disease , Higher Dose, Weight-Based Therapy Justified ... 27, 2007) -- As reported recently in the ... 5,000 patients with hepatitis C virus (HCV) showed ...
... VALLEJO, Calif., Dec. 27 Sutter Solano Medical Center,(SSMC) ... Winner. The hospital,was recognized in the Emergency Department (ED) ... scores compared to all,other facilities being measured., The ... achievement in the,health care industry that is bestowed annually, ...
... ALTO, Calif., Dec. 27 Garry W. Rogerson,President and ... the 26th,annual JPMorgan Healthcare Conference in San Francisco on ... A live webcast of the presentation will be publicly ... Go to, http://www.varianinc.com and click on "Investors." An ...
... National Institute of Environmental Health Sciences (NIEHS), part ... a total of $6.8 million for the first ... called DISCOVER - Disease Investigation Through Specialized Clinically-Oriented ... are expected to bridge the gap between basic ...
Cached Medicine News:Health News:Western Reserve Heart Care Receives ICAEL Echocardiography Accreditation 2Health News:Cell-death receptor links cancer susceptibility and inflammation 2Health News:In largest U.S. Hep C trial, researchers determine weight-based dosing is key to optimal treatment 2Health News:In largest U.S. Hep C trial, researchers determine weight-based dosing is key to optimal treatment 3Health News:In largest U.S. Hep C trial, researchers determine weight-based dosing is key to optimal treatment 4Health News:Sutter Solano Medical Center Wins National Improvement Award 2Health News:NIEHS awards DISCOVER grants 2Health News:NIEHS awards DISCOVER grants 3
... The NormoFlow™ System is the only ... during high volume surgical irrigation, especially ... room warm, regardless of length of ... provides safe, consistent performance and is ...
... The Hemokinetitherm is a ruggedly built, simple ... stable temperature for the controlled warming of blood ... This temperature is maintained by a water reservoir ... by a proportional controller which is backed up ...
Are you looking for an inexpensive, effective Blood and Infusion Warmer? , ,Animec is an economical fluid warmer that uses standard I.V. tubing instead of special disposable sets....
... complete anesthesia solution for the MRI environment , ... , ,The Narkomed MRI-2 is the ... VPO monitor, designed and engineered to perform, without ... MRI environments of up to 3.0 Tesla. This ...
Medicine Products: